Myriad Genetics (MYGN) announced a study revealing that more patients completed hereditary cancer testing when they used an online screening tool and received education about genetic testing. The study was published in Obstetrics & Gynecology and was highlighted in the American College of Obstetricians and Gynecologists Daily Bulletin. The study evaluated the change in genetic testing completion rate following the implementation of MyGeneHistory, a guideline-based online patient screening tool, and a virtual patient education program. It found that the online tool enabled identification of significantly more patients meeting guideline-based criteria for hereditary cancer testing, while the education program improved the patients’ understanding of genetic testing.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MYGN:
- Myriad Genetics sees Q4 adjusted EPS 3c-4c, consensus 3c
- Myriad Genetics sees FY24 adjusted EPS 14c-15c, consensus 13c
- Myriad Genetics sees FY25 adjusted EPS 7c-11c, consensus 9c
- Myriad Genetics, MD Anderson forms 5-year strategic alliance
- Myriad Genetics price target lowered to $13 from $15 at BofA
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue